Tatva Chintan Pharma Chem Announces Annual Financial Results and Recommends 20% Dividend for FY 2025-26
Tatva Chintan Pharma Chem Limited today, May 16, 2026, announced the audited financial results for the quarter and full financial year ended March 31, 2026. The company's Board of Directors approved key operational updates, including the appointment of external auditors for the fiscal year 2026-27 and recommending a final dividend of 20% per equity share.The company also provided comprehensive statements, including consolidated and standalone financial results, assets and liabilities, and cash flows, offering a detailed financial overview for the period.
Key Board Approvals and Appointments
During the Board meeting held on May 16, 2026, the directors approved several key appointments for the financial year 2026-27:- Cost Auditor: M/s. Zarna Thakar & Associates, Cost Accountants, was appointed as the Cost Auditor for the financial year 2026-27. M/s. Zarna Thakar & Associates is noted for its expertise in Cost Audit and internal controls.
- Internal Auditor: RSM Astute Consultech Private Limited was appointed as the Internal Auditor for the financial year 2026-27. RSM Astute Consultech Private Limited is part of RSM International, a group with a Pan-India presence.
The Board also recommended a Final Dividend of Rs. 2/- (representing 20% of the face value of Rs. 10/- per equity share) for the financial year 2025-26. This dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting.
Financial Highlights: Year Ended March 31, 2026
The financial results for the quarter and full year ended March 31, 2026, reflect the company's operational performance. The statutory auditors, M/s. NDJ & Co., issued an unmodified opinion on the audited financial results for both standalone and consolidated statements.The consolidated statement of financial results provides a summary of the year's performance:
| Particulars (Indian Rupees in million) | Quarter ended 31.03.2026 (Audited) | Year ended 31.03.2026 (Audited) |
|---|---|---|
| Total Income (1+2) | 1,337.96 | 3,850.29 |
| Total Expenses | 1,154.10 | 3,774.50 |
| Profit Before Tax (PBT) | 176.58 | 75.79 |
| Total Comprehensive Income | 156.48 | 64.20 |
| Earnings Per Share (Basic) | 6.49 | 2.44 |
Balance Sheet Overview
The company's financial position as of March 31, 2026, shows total assets and total equity:Consolidated Statement of Assets and Liabilities as at 31 March 2026
| Particulars (Indian Rupees in million) | 31.03.2026 (Audited) |
|---|---|
| Non-Current Assets | |
| Total non-current assets | 6,541.82 |
| Current Assets | |
| Total current assets | 3,495.12 |
| Total Assets | 10,036.94 |
| Total Equity | |
| Equity attributable to owners | 7,817.59 |
| Total Liabilities | |
| Total current liabilities | 2,131.35 |
| Total Equity and Liabilities | 10,036.94 |
Statement of Cash Flows
The cash flow statement indicates the company’s primary source and usage of funds for the year.Consolidated Statement of Cash Flows for the Year Ended 31 March 2026
| Particulars (Indian Rupees in million) | 31.03.2026 (Audited) | 31.03.2025 (Audited) |
|---|---|---|
| Cash generated from operating activities | 314.89 | 247.74 |
| Cash used in investing activities | (653.84) | (762.72) |
| Cash generated from financing activities | 165.93 | 111.74 |
| Net cash generated from operating activities | 314.89 | 247.74 |
| Cash and cash equivalents at the end of the year | 113.74 | 92.05 |
For a complete review of the financial performance, the detailed Standalone and Consolidated Statements of Financial Results, Assets and Liabilities, and Cash Flows are available.
TATVA Stock Price Movement
On Friday, Tatva Chintan Pharma Chem Limited shares edged higher, gaining 5.72% to close at ₹1316.30. The stock saw robust trading action throughout the session, registering a total volume of 64,976 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: